

1 **Mask mandate and use efficacy for COVID-19 containment in US States**

2

3 Damian D. Guerra<sup>1,\*</sup> and Daniel J. Guerra<sup>2</sup>

4

5 1. Department of Biology, University of Louisville, Louisville, Kentucky, United States of America

6 2. Authentic Biochemistry, VerEvMed, Clarkston, Washington, United States of America

7

8 \* Corresponding author ([damian.guerra@louisville.edu](mailto:damian.guerra@louisville.edu))

9

10 **Abstract**

11 *Background:* COVID-19 pandemic mitigation requires evidence-based strategies. Because COVID-19 can spread  
12 via respired droplets, most US states mandated mask use in public settings. Randomized control trials have not  
13 clearly demonstrated mask efficacy against respiratory viruses, and observational studies conflict on whether mask  
14 use predicts lower infection rates. We hypothesized that statewide mask mandates and mask use were associated  
15 with lower COVID-19 case growth rates in the United States.

16 *Methods:* We calculated total COVID-19 case growth and mask use for the continental United States with data from  
17 the Centers for Disease Control and Prevention and Institute for Health Metrics and Evaluation. We estimated post-  
18 mask mandate case growth in non-mandate states using median issuance dates of neighboring states with mandates.

19 *Results:* Earlier mask mandates were not associated with lower total cases or lower maximum growth rates. Earlier  
20 mandates were weakly associated with lower minimum COVID-19 growth rates. Mask use predicted lower  
21 minimum but not lower maximum growth rates. Growth rates and total growth were comparable between US states  
22 in the first and last mask use quintiles during the Fall-Winter wave. These observations persisted for both natural  
23 logarithmic and fold growth models and when adjusting for differences in US state population density.

24 *Conclusions:* We did not observe association between mask mandates or use and reduced COVID-19 spread in US  
25 states. COVID-19 mitigation requires further research and use of existing efficacious strategies, most notably  
26 vaccination.

27

28 **Keywords:** COVID-19, SARS-CoV-2, face covering, medical mask, mask mandate, nonpharmaceutical intervention

## 29 **Introduction**

30 The COVID-19 pandemic has increased mortality and induced socioeconomic upheaval worldwide (1).  
31 Evidence-based containment strategies are warranted, given that age, obesity, cardiovascular disease, and  
32 diabetes are common comorbidities associated with severe COVID-19 symptoms (e.g., pneumonia, blood  
33 clots, cytokine storm), hospitalization, and death (2, 3). Respirated droplets and aerosols containing SARS-  
34 CoV-2 are intuitive modes of community transmission (4). To reduce viral spread, governments have  
35 issued mandates to wear medical masks or cloth face coverings in public settings. From April to  
36 December 2020, 40 States of the United States issued mask mandates. Mask mandates have limited  
37 precedent, making efficacy unclear. Our first objective was to evaluate the efficacy of mask mandates in  
38 attenuating COVID-19 growth in US states.

39  
40 Prior studies have conflicted on whether masks reduce COVID-19 spread. For USS Theodore Roosevelt  
41 crew, mask use was lower among COVID-19 cases compared with non-infected (56% vs. 81%) (5). There  
42 were no infections for 48% of universally masked patrons exposed to COVID-19 positive hair stylists (6),  
43 but PCR tests were not obtained for the other 52% of patrons (6), and first wave COVID-19  
44 hospitalizations were no higher in public schools (high density with minimal masking) than elsewhere in  
45 Sweden (7). A randomized controlled trial (RCT) of Danish volunteers found no protective benefit of  
46 medical masks against COVID-19 infection (8). In RCTs before COVID-19, viral infections were not  
47 lower in Vietnamese clinicians who wore cloth or medical masks than in the control arm (9), and N-95  
48 respirators (but not medical masks) protected Beijing clinicians from bacterial and viral diseases  
49 compared to no masks (10). Mask compliance in RCTs is not always clear (11). Mask use was 10% and  
50 33% for Beijing households with and without intrahousehold COVID-19 case growth, respectively (12).  
51 This suggests greater mask use may reduce COVID-19 spread. Our second objective was to assess if  
52 mask use predicts lower COVID-19 case growth.

53

54 We assessed if mask mandates and compliance in US States predict statewide COVID-19 growth during  
55 the second and third infection waves (1 June 2020-1 March 2021). Controlling for infection wave timing  
56 with logarithmic and linear relative growth models, we found limited association between COVID-19  
57 case growth and mask mandates or mask use before 1 October 2020, and no association during the  
58 subsequent and largest third wave. These findings do not support the hypothesis that statewide mandates  
59 and enhanced mask use slow COVID-19 spread. Pharmaceutical interventions (including recently  
60 available COVID-19 vaccines) provide alternative, evidence-based strategies to minimize COVID-19  
61 related morbidity and mortality.

62

## 63 **Materials and methods**

### 64 *Data Sources and Terms*

65 We obtained total (confirmed and probable) COVID-19 cases up to 6 March 2021 for the 49 continental  
66 US states, normalized per 100,000 residents, from the Centers for Disease Control and Prevention (CDC)  
67 (13). To reduce reporting lag effects, we used 7-day simple moving means (e.g., the 7-day simple moving  
68 mean of cases on 31 March is the mean of daily cases between 28 March and 3 April). Hawaii was  
69 excluded because COVID-19 growth patterns deviated from those of continental US states. Confirmed  
70 and probable cases are defined by the Council of State and Territorial Epidemiologists. Confirmed cases  
71 require PCR amplification of SARS-CoV-2 RNA from patient specimens. Probable cases require one of  
72 the following: clinical and epidemiologic evidence, clinical or epidemiologic evidence supported by  
73 SARS-CoV-2 antigen detection in respiratory specimens, or vital records listing COVID-19 as  
74 contributing to death. Total PCR tests for each state were obtained from Worldometers on 25 May 2021  
75 (14).

76 Mask mandates are statewide emergency executive public health orders requiring nose and mouth  
77 coverings in public settings in more than 50% of counties within a state (15, 16). We assigned US states  
78 to one of five quintiles based on when mandates went into effect (effective dates): 18 April-16 May 2020

79 (Q1), 29 May-3 July 2020 (Q2), 8 July-27 July 2020 (Q3), 1 Aug-9 Dec 2020 (Q4), or no statewide  
80 mandate as of 6 March 2021 (Q5). Effective dates were obtained from US state executive and health  
81 departments and press releases (available upon request).

82 We assessed mask use with the University of Washington Institute for Health Metrics and Evaluation  
83 (IHME) COVID-19 model site (17), which estimates daily compliance from Premise, the Facebook  
84 Global Symptom Survey (University of Maryland), the Kaiser Family Foundation, and the YouGov  
85 Behavior Tracker Survey. Mask use is the percentage of people who always wear masks in public  
86 settings. We assigned US states to mask quintiles based on the mean percent mask use from 1 Jun-1 Oct  
87 2020 (Summer) or from 1 Oct 2020-1 Mar 2021 (Fall-Winter).

88 To assess geographic differences, we assigned each US state to one of five regions: Northeast  
89 (Connecticut, Delaware, Massachusetts, Maryland, Maine, New Hampshire, New Jersey, New York,  
90 Pennsylvania, Rhode Island, and Vermont); Midwest (Illinois, Indiana, Iowa, Kentucky, Kansas,  
91 Michigan, Minnesota, Missouri, Ohio, West Virginia, Wisconsin); Mountains-Plains (Colorado, Idaho,  
92 Montana, Nebraska, New Mexico, North Dakota, Oklahoma, South Dakota, Utah, Wyoming); South  
93 (Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, South Carolina,  
94 Tennessee, Texas, Virginia); and Pacific (Alaska, Arizona, California, Nevada, Oregon, Washington).

95

#### 96 *Growth Rate Calculation*

97 COVID-19 growth has been modeled logarithmically (15, 18, 19) and linearly (19, 20). Therefore, we  
98 calculated COVID-19 case growth for each US state by measuring percent natural logarithmic (Ln  
99 Growth) and percent linear (Fold Growth) relative growth rates:

100 
$$\text{Ln Growth} = 100 * \ln \frac{C_t}{C_{t-1}}$$

101 
$$\text{Fold Growth} = 100 * \left(-1 + \frac{C_t}{C_{t-20}}\right)$$

102 Where  $C_t$ ,  $C_{t-1}$ , and  $C_{t-20}$  are total normalized cases on a day, the prior day, and 20 days prior, respectively.

103 We determined adjusted population density by calculating the weighted mean of each state's urban (U)

104 and rural (R) population density using the following formulas:

$$105 \text{ Urban Density (U)} = u_1p_1 + u_2p_2 + u_3p_3$$

$$106 \text{ Mean Rural Density (R)} = \frac{\text{State Population} * (1-F)}{\text{State Area} - a_1 + a_2 + a_3}$$

107 For the three most populous urban regions in each US state, we obtained urban population density ( $u$ ;

108 people/square mile in an urban area), urban land area ( $a$ ; size of urban area in square miles), and

109 population proportion ( $p$ ; fraction of combined urban population) via 2010 US Census Bureau estimates

110 (21). For some states, two rather than three urban regions were used. The proportion of urban (F) and

111 rural (1-F) population of each state was similarly obtained (21). We thus calculated adjusted population

112 density of each state as:

$$113 \text{ Adjusted Population Density (APD)} = UF + R(1 - F)$$

114 To assess association between population density and growth rates, we multiplied Fold Growth by the

115 inverse of normalized APD:

$$116 \text{ Adj. Fold Growth} = \text{Fold Growth} * \left( \frac{\text{Mean APD of all US States}}{\text{State APD}} \right)$$

117 We defined minima and maxima (extrema) as the lowest and highest growth rates between the end of the

118 Summer wave and the height of the Fall-Winter wave. Ln Growth extrema comprised 20-day windows

119 when Ln Growth rates were lowest or highest:

$$120 \text{ Ln Growth extremum} = \max/\min_{20 \text{ Jul } 2020 \leq t \leq 1 \text{ Mar } 2021} \frac{\sum_{t=1}^{t=20} \text{Ln Growth on Day } t}{20}$$

121 Fold Growth extrema similarly comprise the lowest and highest Fold Growth:

$$122 \text{ Fold Growth extremum} = \max/\min_{20 \text{ Jul } 2020 \leq t \leq 1 \text{ Mar } 2021} \text{Fold Growth}(t-20, t)$$

123 For each state, surges are differences between maxima and minima (relative growth rate increase), masks

124 at extrema are the 20-day mean mask use at minima and maxima, and  $\Delta \text{Masks}$  is the percent change in

125 mask use between maxima and minima.

126 To assess association between mandates and growth rates in the 48 contiguous states (excluding Alaska  
127 and Hawaii), we determined Ln, Fold, and Adj. Fold Growth between 1 March 2021 ( $C_{301}$ ) and the  
128 mandate effective date ( $C_M$ ) for US states in mandate quintiles 1-3:

129 
$$\text{Post-Mandate Ln Growth} = 100 * \ln \frac{C_{301}}{C_M}$$

130 
$$\text{Post-Mandate Fold Growth} = 100 * (-1 + \frac{C_{301}}{C_M})$$

131 For states in quintiles 4-5, *modeled effective dates* are medians of actual dates among bordering states of  
132 mandate quintiles 1-3. For example, the modeled effective date of Tennessee (10 July) is the median of  
133 effective dates of Arkansas (20 July), Alabama (16 July), Kentucky (10 July), North Carolina (26 June),  
134 and Virginia (29 May).

135 For each state, Summer 2020 (1 June-1 Oct) and Fall-Winter 2020-21 (1 Oct-1 Mar) mask use is mean  
136 mask use between these dates. Cases on 1 June or 1 Oct were the 20-day mean total normalized cases on  
137 these two dates. We likewise defined Summer and Fall-Winter case growth using Ln and Fold Growth  
138 formulas:

139 
$$\text{Summer Ln Growth} = \ln \frac{C_{1001}}{C_{601}} \quad \text{Summer Fold Growth} = 100 * (-1 + \frac{C_{1001}}{C_{601}})$$

140 
$$\text{Fall-Winter Ln Growth} = \ln \frac{C_{301}}{C_{1001}} \quad \text{Fall-Winter Fold Growth} = 100 * (-1 + \frac{C_{301}}{C_{1001}})$$

141 Where  $c_{601}$ ,  $c_{1001}$ , and  $c_{301}$  are total normalized cases on 1 June 2020, 1 October 2020, and 1 March 2021,  
142 respectively.

143

#### 144 *Statistics*

145 We used Prism 9.2 (GraphPad; San Diego, CA) to construct figures and perform null hypothesis  
146 significance tests, for which the significance threshold was  $p < \alpha = 0.05$  (**Worksheet D in S1 Table**).

147 Error bars denote standard deviations, 95% confidence intervals, or interquartile ranges as indicated in  
148 figure legends. We performed D'Agostino-Pearson tests to assess normality of residuals.

149 To evaluate mask mandate and use efficacy among categories (mandate effective date or mask use  
150 quintiles), we performed ordinary one-way ANOVA with Tukey posttests. For non-normal data, we  
151 performed Kruskal-Wallis with Dunn posttests. For two sample comparisons (e.g., **Fig. 3G, J**), we  
152 conducted two-tailed t tests or Mann-Whitney tests for normal and non-normal data, respectively.  
153 This decision tree conforms with recommended practices for datasets of  $N > 5$  (22).  
154 For interval variable associations, we performed ordinary least squares (OLS)-simple linear regression  
155 with null hypotheses of zero slope. Infectious disease research has employed OLS previously (23, 24),  
156 with linear and ln-linear models reported in recent COVID-19 studies (25, 26). For the Summer wave,  
157 Northeast states were excluded because they deviated from other states with respect to total cases and  
158 growth covariation. We used weighted least squares (WLS) for heteroscedastic data, as determined by the  
159 GraphPad Prism Test for Homoscedasticity. Regardless of statistical significance,  $R^2$  values denote  
160 coefficients of determination for lines of best fit with unconstrained slopes.

161

## 162 **Results**

### 163 *COVID-19 growth rates vary with time*

164 With the aim of reducing COVID-19 case growth, 40 US states enacted mask mandates in 2020. We  
165 wondered if mask mandate timing affected COVID-19 growth patterns. To identify patterns of COVID-  
166 19 growth, we graphed natural logarithmic (Ln) Growth of COVID-19 in US states as a function of time  
167 (**Worksheet A in S1 Table**). We observed six phases of COVID-19 growth up to 6 March 2021: first  
168 wave (before May 2020), Spring minimum (May-June 2020), Summer wave maximum (June-August  
169 2020), post-Summer minimum (August-October 2020), Fall-Winter wave maximum (October-January  
170 2020), and third minimum (March 2021) (**Fig. 1A and S1 Fig**). Hawaii growth patterns deviated from  
171 those of continental US states and was thus excluded from further analysis. Regardless of mask mandate  
172 effective date quintile, Ln growth patterns were comparable for all continental US states, and there was no  
173 association between normalized total cases and PCR tests (**S1 Fig**).

174

175 *Earlier mask mandates are not consistently associated with COVID-19 growth rates in US states*

176 A recent study reported time-enhanced negative association between mask mandates and Ln Growth of  
177 COVID-19 (15), but simple Fold-Growth (an alternative COVID-19 metric (19, 20)) may be preferred for  
178 post-exponential, linear pandemic spread. PCR testing for COVID-19 was limited before Summer 2020  
179 (27). Thus, to determine if US states with earlier mask mandates exhibited less COVID-19 spread, we  
180 examined both Ln Growth and Fold Growth at the post-Summer wave minimum and the Fall-Winter  
181 wave maximum (**Fig 1A-B**)—periods of low and high transmission, respectively. We assigned US states  
182 to one of five quintiles (MQ1-5), with MQ1 including states with the earliest mandates, MQ4 the latest  
183 mandates, and MQ5 states without mandates. Ln minima ( $p=0.07$ ; **Fig. 1C**) and Fold minima ( $p=0.047$ ;  
184 **Fig. 1D**) trended lower for earlier mandates. Fold minima was 3-fold higher in MQ4 than MQ1 after  
185 adjusting for population density ( $p=0.04$ ), but all other pairwise comparisons were not significant (**Fig.**  
186 **1E**). This suggested that mask mandate duration was a weak predictor of lower minimum growth. Ln  
187 maxima ( $p=0.23$ ; **Fig. 1F**) and Fold maxima ( $p=0.19$ ; **Fig. 1G**) did not differ among quintiles. Adjusting  
188 for population density, Fold maxima were 2.8-fold higher in MQ4 than MQ2 ( $p=0.01$ ), but MQ1, 3, and 5  
189 were indistinguishable (**Fig. 1H**), suggesting mask mandate duration was not associated with lower  
190 maximum growth. Likewise, surges (growth rate increases from minima to maxima) were MQ-  
191 independent for Ln ( $p=0.08$ ) and Fold ( $p=0.13$ ) models, and only MQ2 and MQ4 exhibited significantly  
192 different Fold surges with population density adjustment ( $p=0.03$ ; **S2 Fig**). Most MQ4 states exhibited  
193 lower initial and Summer 2020 infection waves than Q1-2 (**S1 Fig**), suggesting high MQ4 growth rates  
194 could be an artifact of lower total cases. While there was strong positive association between earlier  
195 mandates and Fall-Winter mask use ( $p<0.001$ ; **Fig. 1I**), total cases on 1 March 2021 were MQ-  
196 independent ( $p<0.07$ ; **Fig. 1J**). Direct MQ1 vs. MQ5 comparison by t test uncovered a small (1.2-fold)  
197 and non-significant ( $p=0.078$ ) difference in total cases. Taken together, these findings suggest that US  
198 state mask mandates were not associated with slower spread of COVID-19.

199



200 *Early mask mandates do not predict lower post-mandate COVID-19 growth in contiguous US states*

201 Most US states enacted mandates during infection waves, which confounds assessment of effectiveness.

202 To assess association between mandate effective date and post-mandate case growth, we compared

203 growth after actual MQ1-3 mandates with growth after modeled MQ4-5 mandates up to 1 March 2021.

204 For a MQ4-5 state, the modeled date was the effective date median of contiguous, common-border MQ1-

205 3 states (**Fig. 2A**). Post-mandate growth in total cases was MQ-independent by Ln ( $p=0.43$ ), Fold ( $p=41$ ),

206 and population density-adjusted Fold ( $p=0.15$ ) models (**Fig. 2B**). Direct MQ1 vs. MQ5 comparison by

207 Mann-Whitney test uncovered a small (1.3-fold) and non-significant ( $p=0.86$ ) difference in adjusted fold-

208 growth. Overall, we did not obtain an association between mandates and lower COVID-19 growth.

209

210 *Mask use is not associated with most state COVID-19 case growth*

211 We speculated that statewide mask use, rather than mask mandates per se, may predict lower COVID-19

212 growth rates. The Institute of Health Metrics and Evaluation (IHME) provides robust estimates for mask

213 use (defined as the percentage of people who always wear masks in public settings) (17). By simple linear

214 regression, mask use was associated with lower Ln, Fold, and adjusted Fold minima ( $p<0.0001$ ; **Fig 3A-B**

215 and **S3A Fig**). To better understand this trend, we assigned US states to one of five mask use quintiles

216 (UQ1-5), with UQ1 including states with the highest mask use and UQ5 states with the lowest mask use.

217 UQ5 exhibited a 3.4-fold greater adjusted Fold minimum than UQ1 ( $p=0.002$ ; **Fig 3C**), suggesting

218 potential association between mask use and COVID-19 spread at minima. By contrast, mask use was not

219 associated with Ln ( $p=0.071$ ), Fold ( $p=0.058$ ), or adjusted Fold ( $p=0.076$ ) maxima (**Fig 3D-E** and **S3D**

220 **Fig**). Adjusted Fold maxima were also UQ-independent ( $p=0.56$ ; **Fig 3F**), with direct UQ1 vs. UQ5

221 comparison by Mann-Whitney test uncovering a modest (1.5-fold) and non-significant ( $p=0.16$ )

222 difference in maxima. This suggests that mask use is not associated with COVID-19 spread at maxima.

223

224 We wondered why mask use was associated with lower minimum but not lower maximum growth rates.

225 Mask use was not associated with total cases at Ln minima ( $p=0.54$ ) or maxima ( $p=0.086$ ; **S3C-D Fig**),

226 indicating potential confounders in the mask-minimum growth relationship. Excluding Northeast states,  
227 which exhibited the largest first waves and July 2020 seroprevalence (13, 28), total cases predicted lower  
228 Ln minima ( $p=0.001$ ; **S3E Fig**). This suggested that the link between mask use and lower minima may be  
229 an artifact of the tendency for faster case growth to occur at lower case prevalence. In support of this, for  
230 1 June – 1 Oct. 2020 mask use quintiles, normalized cases grew from 400 to 1350 at similar rates for UQ1  
231 (which includes eight Northeast states) and UQ5 ( $p=0.22$ ; **Fig. 3G**). UQ5 exhibited exponential growth  
232 and reached these case totals ~50 days after UQ1 (**Fig 3H-I**), further implying that higher growth rates  
233 may reflect lower total cases in low mask use states before minima. 0-80 days after Ln maxima, when  
234 total case differences were smaller among states, UQ1 and UQ5 exhibited indistinguishable growth rates  
235 ( $p=0.78$ ; **Fig 3J**; 1 Oct. 2020 – 1 March 2021 mask use quintiles). Growth was post-exponential for both  
236 UQ1 and UQ5 during this period (**Fig 3K-L**), and total cases predicted lower Ln maxima in all  
237 continental US states ( $p<0.0001$ ; **S3F Fig**). Together, these data suggest that mask use is an unreliable  
238 predictor of COVID-19 growth in US states.

239

240 *Mask use does not predict Summer or Fall-Winter COVID-19 cumulative growth in US states.*

241 As expected, total cases were negatively associated with Ln growth in non-Northeast states for 1 June-1  
242 Oct. 2020 and all continental US states for 1 Oct. 2020 – 1 March 2021 ( $p<0.0001$ ; **S4A-B Fig**). We  
243 reasoned that even if mask use could not predict growth rate, mask use may be negatively associated with  
244 cumulative case growth. 1 June-1 Oct. 2020 (Summer) 1 Oct. 2020 – 1 March 2021 (Fall-Winter)  
245 represent two distinct COVID-19 growth waves (**Fig 4A-B**). Excluding Northeast states, masks were not  
246 associated with lower Summer growth using Ln ( $p=0.11$ ; **Fig 4C**) or Fold ( $p=0.18$ ; **S4C Fig**) models.  
247 Mask use trended with lower adjusted Fold Summer growth ( $p=0.05$ ; **S4D Fig**). While adjusted Fold  
248 Summer growth was 3-fold higher in UQ4 than UQ1 ( $p=0.009$ ), all other pairwise comparisons were not  
249 significant (**Fig. 4D**). Likewise, mask use was not associated with lower Fall-Winter growth using Ln  
250 ( $p=0.94$ ; **Fig 4E**), Fold ( $p=0.91$ ; **S4E Fig**), or adjusted Fold ( $p=0.71$ ; **S4F Fig**) models, and adjusted Fold  
251 Fall-Winter growth was not significantly different among mask use quintiles ( $p=0.38$ ; **Fig. 4F**). These

252 data suggest that mask use is not consistently associated with Summer wave growth and not associated  
253 with Fall-Winter wave growth in US states. Furthermore, low Summer growth did not protect Northeast  
254 states from subsequent Fall-Winter growth. In summary, statewide SARS-CoV-2 transmission waves  
255 appear independent of reported mask use (17).

256

## 257 **Discussion**

258 Our main finding is that mask mandates and use likely did not affect COVID-19 case growth. Mask  
259 mandates were associated with greater mask use but ultimately did not influence total normalized cases or  
260 post-mandate case growth. Higher mask use (rather than mandates per se) has been argued to decrease  
261 COVID-19 growth rates (11). While compliance varies by location and time, IHME estimates are derived  
262 from multiple sources and densely sampled. Even when accounting for population density, higher mask  
263 use was not associated with lower Ln or fold maximum growth rates or lower Fall-Winter case growth  
264 among continental US states. By contrast, mask use-growth rate association was highly significant at  
265 minima. This antinomy warrants consideration. Mask use did not predict normalized cases at growth  
266 minima or maxima, whereas there were more cases in the highest than the lowest mask use quintile before  
267 minima. Northeast states exhibited the highest seroprevalence by July 2020 (28) and comprised 80% of  
268 the highest mask use quintile, suggesting that mask use may be a lagging indicator of case growth. At  
269 maxima, when case prevalence was similar among states, COVID-19 growth rates were also similar for  
270 the highest and lowest mask use quintiles. Thus, initial association between masks and lower COVID-19  
271 growth rates that dissipated during the Fall-Winter 2020-21 wave is likely an artifact of fewer normalized  
272 cases begetting faster growth in states with coincidental low mask use.

273

274 There is inferential but not demonstrable evidence that masks reduce SARS-CoV-2 transmission. Animal  
275 models (29), small case studies (6), and growth curves for mandate-only states (16) suggest that mask  
276 efficacy increases with mask use (11). However, we did not observe lower growth rates over a range of

277 compliance at maximum Fall-Winter growth (45-83% between South Dakota and Massachusetts during  
278 maxima) (17) when growth rates were high. This complements a Danish RCT from 3 April to 2 June  
279 2020, when growth rates were low, which found no association between mask use and lower COVID-19  
280 rates either for all participants in the masked arm (47% strong compliance) or for strongly compliant  
281 participants only (8). While N-95 respirators offer some protection against respiratory viruses (10), there  
282 is limited evidence for cloth and medical masks. Higher self-reported mask use protected against SARS-  
283 CoV-1 in Beijing residents (30), but RCTs found no differences in PCR confirmed influenza among Hong  
284 Kong households assigned to hand hygiene with or without masks (mask use 31% and 49%, respectively)  
285 (31). Medical and cloth masks did not reduce viral respiratory infections among clinicians in Vietnam (9)  
286 or China (10), and rhinovirus transmission increased among universally masked Hong Kong students and  
287 teachers in 2020 compared with prior years (32). These findings are consistent with a 2020 CDC meta-  
288 analysis (33) and a 2020 Cochrane review update (34).

289  
290 Our study has implications for respiratory virus mitigation. Public health measures should ethically  
291 promote behaviors that prevent communicable diseases. The sudden onset of COVID-19 compelled  
292 adoption of mask mandates before efficacy could be evaluated. Our findings do not support the  
293 hypothesis that greater public mask use decreases COVID-19 spread. As masks have been required in  
294 many settings, it is prudent to weigh potential benefits with harms. Masks may promote social cohesion  
295 during a pandemic (35), but risk compensation can also occur (36). By obscuring nonverbal  
296 communication, masks interfere with social learning in children (37). Likewise, masks can distort verbal  
297 speech and remove visual cues to the detriment of individuals with hearing loss; clear face-shields  
298 improve visual integration, but there is a corresponding loss of sound quality (38, 39). Prolonged mask  
299 use (>4 hours per day) promotes facial alkalization and inadvertently encourages dehydration, which in  
300 turn can enhance barrier breakdown and bacterial infection risk (40). British clinicians have reported  
301 masks to increase headaches and sweating and decrease cognitive precision (41). Survey bias  
302 notwithstanding, these sequelae are associated with medical errors (42). Future research is necessary to

303 assess risks of long-term daily mask use (34). As COVID-19 remains a public health threat, it is also  
304 appropriate to emphasize interventions with demonstrated efficacy against COVID-19, most notably  
305 vaccination (43) and vitamin D repletion (44).

306

307 In conclusion, we found mask mandates and use to be poor predictors of COVID-19 spread in US states.

308 Strengths of our study include assessing COVID-19 association with both mandates and reported use;

309 evaluating both Ln and Fold growth models; accounting for population density differences; and

310 measuring case growth after modeled mandate effective dates in states with late or no mandates. Our

311 study also has key limitations. We did not assess counties or localities, which may trend independently of

312 state averages. While dense sampling promotes convergence, IHME masking estimates are subject to

313 survey bias. We only assessed one biological quantity (confirmed and probable COVID-19), but the

314 ongoing pandemic warrants assessment of other factors such as hospitalizations and mortality.

315 Importantly, our study does not disprove the efficacy of all masks in limited and controlled

316 circumstances, such as properly worn N95 respirators. A recent study found that at typical respiratory

317 fluence rates, medical masks decrease airway deposition of 10-20 $\mu$ m SARS-CoV-2 particles but not 1-

318 5 $\mu$ m SARS-CoV-2 aerosols (45). Aerosol expulsion increases with COVID-19 disease severity in non-

319 human primates, as well as with age and BMI in humans without COVID-19 (46). Together with

320 enhanced vaccination rates, aerosol treatment with improved ventilation and air purification could help

321 reduce the size of COVID-19 outbreaks.

322

323

324

325 **Acknowledgments**

326 The authors thank Brandy Jesernik, Ashley Tracey, Jay Bhattacharya, Scott Atlas, and Erik Fostvedt for  
327 manuscript input.

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347 **References**

- 348 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with  
349 Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33.
- 350 2. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces  
351 cytokine storm with high mortality. *Inflamm Regen*. 2020;40:37.
- 352 3. Chu Y, Yang J, Shi J, Zhang P, Wang X. Obesity is associated with increased severity of disease in  
353 COVID-19 pneumonia: a systematic review and meta-analysis. *Eur J Med Res*. 2020;25(1):64.
- 354 4. Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by  
355 droplets and aerosols: A critical review on the unresolved dichotomy. *Environ Res*. 2020;188:109819.
- 356 5. Payne DC, Smith-Jeffcoat SE, Nowak G, Chukwuma U, Geibe JR, Hawkins RJ, et al. SARS-CoV-2  
357 Infections and Serologic Responses from a Sample of U.S. Navy Service Members - USS Theodore  
358 Roosevelt, April 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(23):714-21.
- 359 6. Hendrix MJ, Walde C, Findley K, Trotman R. Absence of Apparent Transmission of SARS-CoV-2  
360 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield,  
361 Missouri, May 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(28):930-2.
- 362 7. Ludvigsson JF, Engerström L, Nordenhäll C, Larsson E. Open Schools, Covid-19, and Child and  
363 Teacher Morbidity in Sweden. *N Engl J Med*. 2021;384(7):669-71.
- 364 8. Bundgaard H, Bundgaard JS, Raaschou-Pedersen DET, von Buchwald C, Todsén T, Norsk JB, et al.  
365 Effectiveness of Adding a Mask Recommendation to Other Public Health Measures to Prevent SARS-CoV-  
366 2 Infection in Danish Mask Wearers : A Randomized Controlled Trial. *Ann Intern Med*. 2021;174(3):335-  
367 43.
- 368 9. MacIntyre CR, Seale H, Dung TC, Hien NT, Nga PT, Chughtai AA, et al. A cluster randomised trial  
369 of cloth masks compared with medical masks in healthcare workers. *BMJ Open*. 2015;5(4):e006577.
- 370 10. MacIntyre CR, Wang Q, Rahman B, Seale H, Ridda I, Gao Z, et al. Efficacy of face masks and  
371 respirators in preventing upper respiratory tract bacterial colonization and co-infection in hospital  
372 healthcare workers. *Prev Med*. 2014;62:1-7.
- 373 11. Howard J, Huang A, Li Z, Tufekci Z, Zdimal V, van der Westhuizen H-M, et al. An evidence review  
374 of face masks against COVID-19. *Proceedings of the National Academy of Sciences*.  
375 2021;118(4):e2014564118.
- 376 12. Wang Y, Tian H, Zhang L, Zhang M, Guo D, Wu W, et al. Reduction of secondary transmission of  
377 SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing,  
378 China. *BMJ Glob Health*. 2020;5(5).
- 379 13. United States COVID-19 Cases and Deaths by State over Time. Centers for Disease Control and  
380 Prevention (CDC); 2021.
- 381 14. Worldometers.info. Worldometer Dover, DE USA2021 [updated 25 May 2021; cited 2021].  
382 Available from: <https://www.worldometers.info/coronavirus/country/us/>.
- 383 15. Guy GP, Jr., Lee FC, Sunshine G, McCord R, Howard-Williams M, Kompaniyets L, et al.  
384 Association of State-Issued Mask Mandates and Allowing On-Premises Restaurant Dining with County-  
385 Level COVID-19 Case and Death Growth Rates - United States, March 1-December 31, 2020. *MMWR*  
386 *Morb Mortal Wkly Rep*. 2021;70(10):350-4.
- 387 16. Lyu W, Wehby GL. Community Use Of Face Masks And COVID-19: Evidence From A Natural  
388 Experiment Of State Mandates In The US. *Health Aff (Millwood)*. 2020;39(8):1419-25.
- 389 17. Institute for Health Metrics and Evaluation COVID-19 model: University of Washington; 2021  
390 [Available from: <https://covid19.healthdata.org/>].
- 391 18. Liu Z, Fang CT. A modeling study of human infections with avian influenza A H7N9 virus in  
392 mainland China. *Int J Infect Dis*. 2015;41:73-8.
- 393 19. Perneger T, Kevorkian A, Grenet T, Gallée H, Gayet-Ageron A. Alternative graphical displays for  
394 the monitoring of epidemic outbreaks, with application to COVID-19 mortality. *BMC Medical Research*  
395 *Methodology*. 2020;20(1):248.

- 396 20. De Flora S, La Maestra S. Growth and decline of the COVID-19 epidemic wave in Italy from  
397 March to June 2020. *J Med Virol*. 2021;93(3):1613-9.
- 398 21. Bureau USC. 2010 Census Urban and Rural Classification and Urban Area Criteria. In: Commerce  
399 UDo, editor. 2010.
- 400 22. Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. Experimental  
401 design and analysis and their reporting II: updated and simplified guidance for authors and peer  
402 reviewers. *British Journal of Pharmacology*. 2018;175(7):987-93.
- 403 23. Khan A, Waleed M, Imran M. Mathematical analysis of an influenza epidemic model,  
404 formulation of different controlling strategies using optimal control and estimation of basic  
405 reproduction number. *Mathematical and Computer Modelling of Dynamical Systems*. 2015;21(5):432-  
406 59.
- 407 24. Samaras L, Sicilia M-A, García-Barriocanal E. Predicting epidemics using search engine data: a  
408 comparative study on measles in the largest countries of Europe. *BMC Public Health*. 2021;21(1):100.
- 409 25. Ghosal S, Sengupta S, Majumder M, Sinha B. Linear Regression Analysis to predict the number of  
410 deaths in India due to SARS-CoV-2 at 6 weeks from day 0 (100 cases - March 14th 2020). *Diabetes Metab*  
411 *Syndr*. 2020;14(4):311-5.
- 412 26. Chu J. A statistical analysis of the novel coronavirus (COVID-19) in Italy and Spain. *PloS one*.  
413 2021;16(3):e0249037.
- 414 27. Jha AK, Tsai T, Jacobson B. Why we need at least 500,000 tests per day to open the economy —  
415 and stay open: Brown School of Public Health; 2020 [Available from:  
416 [https://globalepidemics.org/2020/04/18/why-we-need-500000-tests-per-day-to-open-the-economy-  
417 and-stay-open/](https://globalepidemics.org/2020/04/18/why-we-need-500000-tests-per-day-to-open-the-economy-and-stay-open/)].
- 418 28. Anand S, Montez-Rath M, Han J, Bozeman J, Kerschmann R, Beyer P, et al. Prevalence of SARS-  
419 CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study.  
420 *Lancet (London, England)*. 2020;396(10259):1335-44.
- 421 29. Chan JF, Yuan S, Zhang AJ, Poon VK, Chan CC, Lee AC, et al. Surgical Mask Partition Reduces the  
422 Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019  
423 (COVID-19). *Clin Infect Dis*. 2020;71(16):2139-49.
- 424 30. Wu J, Xu F, Zhou W, Feikin DR, Lin CY, He X, et al. Risk factors for SARS among persons without  
425 known contact with SARS patients, Beijing, China. *Emerg Infect Dis*. 2004;10(2):210-6.
- 426 31. Cowling BJ, Chan KH, Fang VJ, Cheng CK, Fung RO, Wai W, et al. Facemasks and hand hygiene to  
427 prevent influenza transmission in households: a cluster randomized trial. *Ann Intern Med*.  
428 2009;151(7):437-46.
- 429 32. Fong MW, Leung NHL, Cowling BJ, Wu P. Upper Respiratory Infections in Schools and Childcare  
430 Centers Reopening after COVID-19 Dismissals, Hong Kong. *Emerg Infect Dis*. 2021;27(5).
- 431 33. Fong MW, Gao H, Wong JY, Xiao J, Shiu EYC, Ryu S, et al. Nonpharmaceutical Measures for  
432 Pandemic Influenza in Nonhealthcare Settings-Social Distancing Measures. *Emerg Infect Dis*.  
433 2020;26(5):976-84.
- 434 34. Jefferson T, Del Mar CB, Dooley L, Ferroni E, Al-Ansary LA, Bawazeer GA, et al. Physical  
435 interventions to interrupt or reduce the spread of respiratory viruses. *Cochrane Database of Systematic*  
436 *Reviews*. 2020(11).
- 437 35. Goh Y, Tan BYQ, Bhartendu C, Ong JY, Sharma VK. The face mask: How a real protection  
438 becomes a psychological symbol during Covid-19? *Brain Behav Immun*. 2020;88:1-5.
- 439 36. Yan Y, Bayham J, Richter A, Fenichel EP. Risk compensation and face mask mandates during the  
440 COVID-19 pandemic. *Scientific Reports*. 2021;11(1):3174.
- 441 37. Spitzer M. Masked education? The benefits and burdens of wearing face masks in schools during  
442 the current Corona pandemic. *Trends Neurosci Educ*. 2020;20:100138.



- 443 38. Corey RM, Jones U, Singer AC. Acoustic effects of medical, cloth, and transparent face masks on  
444 speech signals. *J Acoust Soc Am*. 2020;148(4):2371.
- 445 39. Atcherson SR, Finley ET, Renee McDowell BR, Watson C. More Speech Degradations and  
446 Considerations in the Search for Transparent Face Coverings During the COVID-19 Pandemic. *Audiology*  
447 *Today*. 2020;Nov/Dec.
- 448 40. Hua W, Zuo Y, Wan R, Xiong L, Tang J, Zou L, et al. Short-term skin reactions following use of N95  
449 respirators and medical masks. *Contact Dermatitis*. 2020;83(2):115-21.
- 450 41. Davey SL, Lee BJ, Robbins T, Randeve H, Thake CD. Heat stress and PPE during COVID-19: impact  
451 on healthcare workers' performance, safety and well-being in NHS settings. *J Hosp Infect*. 2021;108:185-  
452 8.
- 453 42. Rosenberg K. The joint commission addresses health care worker fatigue. *Am J Nurs*.  
454 2014;114(7):17.
- 455 43. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of  
456 the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*. 2020;383(27):2603-15.
- 457 44. Radujkovic A, Hippchen T, Tiwari-Heckler S, Dreher S, Boxberger M, Merle U. Vitamin D  
458 Deficiency and Outcome of COVID-19 Patients. *Nutrients*. 2020;12(9).
- 459 45. Xi J, Si XA, Nagarajan R. Effects of mask-wearing on the inhalability and deposition of airborne  
460 SARS-CoV-2 aerosols in human upper airway. *Phys Fluids (1994)*. 2020;32(12):123312.
- 461 46. Edwards DA, Ausiello D, Salzman J, Devlin T, Langer R, Beddingfield BJ, et al. Exhaled aerosol  
462 increases with COVID-19 infection, age, and obesity. *Proceedings of the National Academy of Sciences of*  
463 *the United States of America*. 2021;118(8).

464

465

466

467

468

469

470

471

472

473

474

475

476 **Figure Legends**

477 **Fig 1. Earlier mask mandates are not consistently associated with lower COVID-19 growth rates in**  
478 **continental US States.** A-B. Natural logarithmic (A) and Fold (B) COVID-19 growth in continental US  
479 states. Red horizontal lines denote growth rate minima (Min) and maxima (Max) between Summer and  
480 Fall-Winter waves. Surge: growth rate increase between Min and Max. C. Ln minima were not associated  
481 with the time quintile of a state's mandate effective date (MQ). D. Fold minima trended lower in MQ1  
482 than MQs 3 and 5. E. Adjusted Fold minima were lower in MQ1 than MQ4 and indistinguishable for all  
483 other pairwise comparisons. F-G. Ln (F) and Fold (G) maxima were not associated with mandate  
484 effective date time quintiles. H. Adjusted Fold maxima were lower in MQ2 than MQ4 and  
485 indistinguishable for all other pairwise comparisons. I. States with earlier mask mandates exhibited  
486 greater mask use between Oct. 2020 and March 2021. J. Cases per 100,000 by 1 March 2021 were not  
487 associated with mandate effective date time quintiles. Different letters denote  $p < 0.05$  by Tukey tests after  
488 one-way ANOVA (C, F, G) or all pairwise comparison Dunn tests after Kruskal-Wallis (D, E, H-J). \*:  $p < 0.05$   
489 by Kruskal-Wallis. n.s.: not significant. Error bars: 95% confidence intervals (A-B), standard  
490 deviations (C, F, G), and interquartile ranges (D, E, H-J).

491  
492 **Fig 2. Earlier mask mandates are not associated with lower post-mandate COVID-19 growth rates**  
493 **in contiguous US states.** A. Effective and modeled effective (*bold, italicized*) dates in 2020 for mask  
494 mandates in contiguous US states. State colors denote effective date time quintiles. Modeled dates of  
495 MQ4-5 states (late or no actual mandates) are medians of effective dates among bordering states of MQ1-  
496 3 (earlier mandates). Dashed lines denote MQ1-3 states that border a given MQ4-5 state. B-D. Between  
497 actual or modeled mandate effective dates and 1 March 2021, Ln Growth (B), Fold Growth (C), and  
498 population density-adjusted Fold Growth (D) were not associated with mandate effective date time  
499 quintiles. n.s.: not significant by one-way ANOVA (B) or Kruskal-Wallis (C-D). Error bars: standard  
500 deviations (B) and interquartile ranges (C-D).

501

502 **Fig 3. Mask use does not consistently predict COVID-19 case growth in continental US states.** A-C.  
503 At minima, mask use was associated with lower ln (A), fold (B), and population density-adjusted fold (C)  
504 growth rates. D-F. At maxima, mask use was not associated with ln (D), fold (E), or population density-  
505 adjusted fold (F) growth rates. G. States in June-Oct. 2020 mask use quintiles (UQ) 1 and 5 grew from  
506 400 to 1350 normalized cases at indistinguishable rates before minima. H-I. Ln cases (H) and cases (I) vs.  
507 time for UQ1 and UQ5. J. States in Oct. 2020-March 2021 mask use UQ1 and UQ5 exhibited  
508 indistinguishable Fold Growth 80 days after maxima. K-L. Ln cases (K) and cases (L) vs. time for UQ1  
509 and UQ5. Simple linear regression used weighted (A-B) or ordinary (D-E) least squares.  $R^2$  values refer  
510 to unconstrained lines of best fit. Different letters denote  $p < 0.05$  by all pairwise comparison Dunn tests  
511 after Kruskal-Wallis (C, F). n.s.: not significant. Error bars: Interquartile ranges (C, F, J, K) and 95%  
512 confidence intervals (G-H).

513  
514 **Fig 4. Mask use does not predict lower COVID-19 growth during the Summer or Fall-Winter**  
515 **waves.** A-B. Ln Growth rate (A) and total COVID-19 cases (B) for continental US states from 20 April  
516 2020 to 6 March 2021. Red vertical lines denote Summer (Jun-Oct 2020) and Fall-Winter (Oct 2020-Mar  
517 2021) waves. C. Mask use does not predict Summer Ln Growth in non-Northeast states. D. In the  
518 Summer wave, population-adjusted Fold Growth was lower in Summer mask use UQ1 than UQ4 and  
519 indistinguishable among UQ2-5. E. Mask use does not predict Fall-Winter Ln Growth in continental US  
520 states. F. In the Fall-Winter wave, population-adjusted Fold Growth was indistinguishable among Fall-  
521 Winter mask use quintiles. Simple linear regression used ordinary least squares (C, E).  $R^2$  values refer to  
522 unconstrained lines of best fit. Different letters denote  $p < 0.05$  by all pairwise comparison Dunn tests after  
523 Kruskal-Wallis (D, F). n.s.: not significant. Error bars: 95% confidence intervals (A-B) and interquartile  
524 ranges (D, F). Solid circles (●): All continental US states. Hollow circles (○): Excluded Northeast states.

525  
526

## 527 **Supporting Information Legends**

528 **S1 Fig.** A. Natural logarithmic COVID-19 growth rates in continental US states by mask mandate time  
529 quintile. Y-axis values are differences between natural logarithms of total cases on a day and natural  
530 logarithms of total cases on the prior day. States are listed by time quintiles at which mask mandates  
531 became effective statewide. Thin black and wide gray denote mean and 95% confidence intervals,  
532 respectively. Red vertical lines denote dates of mask mandate issuance. Red horizontal lines indicate  
533 growth rate minima (phase 4) and maxima (phase 5) between the Summer and Fall-Winter waves. B.  
534 There is no association between cases and COVID-19 PCR tests among US states (case and test totals as  
535 of 25 May 2021).

536  
537 **S2 Fig. Earlier mask mandates are not consistently associated with lower COVID-19 growth surges**  
538 **in continental US States.** Ln (A) and Fold (B) surges were not associated with the time quintile of a  
539 state's mandate effective date. C. Adjusted Fold maxima were lower in MQ2 than MQ4 and  
540 indistinguishable for all other pairwise comparisons. Different letters denote  $p < 0.05$  by all pairwise  
541 comparison Dunn tests after Kruskal-Wallis (C). n.s.: not significant by one-way ANOVA. Error bars:  
542 standard deviations (A, B) and interquartile ranges (C).

543  
544 **S3 Fig. Inverse association between normalized cases and COVID-19 growth rates in continental**  
545 **US states.** A. At minima, mask use predicts lower population density-adjusted Fold Growth. B. At  
546 maxima, mask use does not predict population density-adjusted Fold Growth. C. Normalized cases do not  
547 predict mask use at minima. D. Normalized cases do not predict mask use at maxima. E. At minima,  
548 greater total cases predict lower growth rates in non-Northeast continental US states. F. At maxima,  
549 greater total cases predict lower growth rates in continental US states at maxima. Black circles (●): All  
550 continental US states. Hollow blue circles (○): Excluded Northeast states. Solid blue circles (●): Included  
551 Northeast states. Red squares (■): Midwest states. Green triangles (▲): Mountain-Plains States. Grey

552 triangles (▼): South states. Gold diamonds (◆): Pacific states. Simple linear regression used ordinary (A-  
553 D, F) or weighted (E) least squares and included all continental states except E (which excluded Northeast  
554 states).  $\epsilon$ : Non-normal residuals by D'Agostino-Pearson test.  $R^2$  values refer to unconstrained lines of best  
555 fit.



556

557 **S4 Fig. Limited association between mask use and COVID-19 case growth during Summer and**  
558 **Fall-Winter waves.** A. Mask use does not predict Summer Fold Growth in non-Northeast states. B. Mask  
559 use is marginally associated with lower population-adjusted Fold Growth in non-Northeast states. C-D.  
560 Normalized cases were associated with lower Ln Growth during Summer (C) and Fall-Winter (D) waves  
561 in non-Northeast states (C) and all continental US states (D), respectively. E-F. Mask use does not predict  
562 Fall-Winter Fold Growth (E) or population-adjusted Fold Growth (F) in continental US states. Simple  
563 linear regression used ordinary least squares and excluded Northeast states (A, C, D) or included all  
564 continental US states (B, E, F).  $\epsilon$ : Non-normal residuals by D'Agostino-Pearson test.  $R^2$  values refer to  
565 unconstrained lines of best fit.


566

567 **S1 Table. Supplemental Data Tables.** Worksheet A. 7-day rolling mean of total normalized cases (cases  
568 per 100,000 residents of each US state from CDC), 31 March 2020 - 1 March 2021. Worksheet B. Natural  
569 logarithmic daily case growth, 1 April 2020 – 1 March 2021. 20-day minima and maxima are denoted in  
570 red and gold, respectively. Mask mandate effective dates and modeled effective dates are provided for  
571 each state. Worksheet C. Population density calculations. See Materials and Methods for explanation of  
572 formulas. Worksheet D. 20-day Fold Growth, 12 August 2020 – 1 March 2021. Minima and maxima are  
573 denoted in red and gold, respectively. Population density-adjusted Fold Growth data are provided for each  
574 state. Worksheet E. Mask use for each US state at Ln and Fold extrema and during the Summer and Fall-  
575 Winter waves. Date range mask use values are simple arithmetic means of daily mask use over the  
576 specified date range. Numeric daily mask use (obtained from IHME) are provided.







577




Mandates Issued by US States (Mandate Quintiles)




Quintile	Mandate Effective Date	Median Cases/100k
1	18 April - 16 May 2020	8841
2	29 May - 3 July 2020	8216
3	8 July - 27 July 2020	9001
4	1 Aug. - 9 Dec. 2020	10077
5	No Statewide Mandate	10005




**I** % Mask Use (Oct 2020-Mar 2021)



**J** Normalized Total Cases (1 Mar 2021)




A




$C_M$ : Cases on effective (MQ<sub>1-3</sub>) or modeled effective (MQ<sub>4-5</sub>) mandate day.


B




C




D




# Mask Use Among US States (Use Quintiles)




## A Masks vs. Ln Minima




## B Masks vs. Fold Minima




## C Adj. Fold Growth at Min Jun-Oct Mask Use Quintiles




## D Masks vs. Ln Maxima



## E Masks vs. Fold Maxima




## F Adj. Fold Growth at Max Oct-Mar Mask Use Quintiles




## G Mean ± 95% CI

	400-1350/100k in __ Days	% Masks Jun-Oct
UQ1	58.7 ±20.8	74 ±1.8
UQ5	73.8 ±17.4	43 ±4.2
p	0.22 (t test)	<0.001 (t test)

## H Ln Cases Pre-Minima UQ1 vs. 5 (Jun-Oct)




## I Cases Pre-Minima UQ1 vs. 5 (Jun-Oct)



## J Median (InterQuartile Range)

	Fold Growth 80 Days Post Max	% Masks Oct-Mar
UQ1	1.45 (1.3-2.0)	80 (78-81)
UQ5	1.31 (1.1-2.2)	61 (55-64)
p	0.78 (Mann-Whitney)	<0.001 (M-W)

## K Ln Cases Post-Max UQ1 vs. 5 (Oct-Mar)



## L Cases Post-Max UQ1 vs. 5 (Oct-Mar)

